Hanna S W Conradi

Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada.

2 papers in the library · 10 citations · publishing 2025-2026

Papers

Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis

Current Oncology June 30, 2025 Haley D M Schuman, Chantal Savard, Raèf Mina et al. 9 citations

A systematic review and meta-analysis of 11 placebo-controlled randomized trials and 4 open-label studies found that psychedelic-assisted therapy with psilocybin or ketamine can reduce depression and anxiety in adults with cancer. Meta-analysis of four ketamine trials (354 participants) showed a large, rapid effect on depression and anxiety. Three psilocybin trials (101 participants) also showed a large effect on depression, though with wide variability. Non-randomized studies of MDMA and LSD suggested promise but were less rigorous. The authors conclude that psychedelic-assisted therapy may offer meaningful relief for cancer-related distress, but effects vary by therapeutic model and context, and more oncology-specific trials are needed.

DOI: 10.3390/curroncol32070380 Anxiety Depression Ketamine Psilocybin +6

Mind-Body Interventions for People With Cancer: Evidence, Innovation, and Implementation.

Seminars in radiation oncology July 1, 2026 Hanna S W Conradi, Jamie N Petersson, Julie M Deleemans et al. 1 citation

Many people with cancer experience persistent psychological and physical challenges such as anxiety, depression, fatigue, pain, sleep problems, fear of recurrence, cognitive issues, and reduced quality of life. Mind-body interventions, which target the connection between mental and physical processes, are increasingly used alongside standard cancer care. This review examines evidence for interventions including mindfulness, yoga, tai chi, qigong, relaxation, hypnosis, music therapy, acupuncture, massage, and aromatherapy, as well as emerging approaches like psychedelic therapy and nature-based interventions. It summarizes target symptoms, treatment timing, and evidence quality, and calls for more rigorous research, understanding of mechanisms, and broader access across diverse populations and all stages of cancer care.

DOI: 10.1016/j.semradonc.2026.151009 Full text